Home » Stocks » PFNX

Pfenex Inc. (PFNX)

Sep 30, 2020 - PFNX was delisted after being acquired by LGND
Stock Price: $12.75 USD 0.00 (0.00%)
Updated Sep 30, 2020 4:00 PM EDT
Market Cap 437.28M
Revenue (ttm) 38.62M
Net Income (ttm) -8.13M
Shares Out 34.29M
EPS (ttm) -0.18
PE Ratio n/a
Forward PE 42.37
Dividend n/a
Dividend Yield n/a
Trading Day Sep 30, 2020
Last Price $12.75
Previous Close $12.75
Change ($) 0.00
Change (%) 0.00%
Day's Open -
Day's Range 12.74 - 12.94
Day's Volume 0
52-Week Range 5.26 - 14.00

News

Hide News
Business Wire - 4 months ago

SAN DIEGO, Calif.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that its tender offer to purchase any and all issued and outstanding shares of common sto...

Other stocks mentioned: LGND
Business Wire - 6 months ago

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

PRNewsWire - 6 months ago

SAN DIEGO, Aug. 12, 2020 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Pfenex Inc.

PRNewsWire - 6 months ago

NEW YORK, Aug. 12, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in Ne...

PRNewsWire - 6 months ago

NEW YORK, Aug. 11, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Pfenex, Inc.

Newsfile Corp - 6 months ago

New York, New York--(Newsfile Corp. - August 11, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Pfenex Inc.

Zacks Investment Research - 6 months ago

Investors need to pay close attention to Pfenex (PFNX) stock based on the movements in the options market lately.

Seeking Alpha - 6 months ago

Pfenex Inc. (PFNX) CEO Eef Schimmelpennink on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 6 months ago

Pfenex (PFNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 7 months ago

SAN DIEGO, July 20, 2020 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) announced today that it will report its financial results for the second quarter ended June 30, 2020, after the...

GlobeNewsWire - 8 months ago

SAN DIEGO, June 26, 2020 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) announced today the achievement of several significant milestones across their business portfolio. Theramex, th...

GlobeNewsWire - 8 months ago

SAN DIEGO, June 12, 2020 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) today announced that its commercialization partner, Alvogen, has launched Teriparatide Injection in the United ...

Seeking Alpha - 9 months ago

Pfenex's (PFNX) CEO Eef Schimmelpennink on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 9 months ago

Pfenex (PFNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 10 months ago

FDA review for a Therapeutic Equivalency rating for PF708 continues FDA review for a Therapeutic Equivalency rating for PF708 continues

Seeking Alpha - 11 months ago

Pfenex Inc. (PFNX) CEO Eef Schimmelpennink on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 11 months ago

Pfenex (PFNX) delivered earnings and revenue surprises of 20.83% and 14.30%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 1 year ago

SAN DIEGO, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) today announced that Serum Institute of India Private Limited (Serum Institute) achieved World Health Organizat...

Seeking Alpha - 1 year ago

Pfenex: Update; Still A Buy For Their Therapeutic Proteins Platform

GlobeNewsWire - 1 year ago

SAN DIEGO, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) today announced that it has earned a $15 million development milestone under its development and license agreem...

GlobeNewsWire - 1 year ago

SAN DIEGO, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX), today announced that Susan Knudson has resigned for personal reasons from her role as Senior Vice President, C...

Seeking Alpha - 1 year ago

Pfenex, Inc. (PFNX) CEO Eef Schimmelpennink on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Pfenex (PFNX) delivered earnings and revenue surprises of 0.00% and 3.03%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Pfenex (PFNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 1 year ago

Study results found that the FDA-approved PF708 product is noninferior to Forteo® based on a pre-specified statistical analysis of critical patient and caregiver tasks

Zacks Investment Research - 1 year ago

Investors need to pay close attention to Pfenex (PFNX) stock based on the movements in the options market lately.

GlobeNewsWire - 1 year ago

New Exclusive Commercialization Agreements in South Korea, Canada, and Israel

InvestorPlace - 1 year ago

Pfenex (PFNX) news for Monday about it getting approval for its new osteoporosis treatment has PFNX stock soaring higher.

GlobeNewsWire - 1 year ago

Pfenex earns a $2.5M milestone payment from Alvogen for U.S. approval

GlobeNewsWire - 1 year ago

SAN DIEGO, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression ...

GlobeNewsWire - 1 year ago

SAN DIEGO, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression ...

GlobeNewsWire - 1 year ago

SAN DIEGO, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) today announced that it has earned an $11 million development milestone under its development and license agre...

GlobeNewsWire - 1 year ago

SAN DIEGO, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression ...

Seeking Alpha - 1 year ago

Pfenex's (PFNX) CEO Eef Schimmelpennink on Q2 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Pfenex (PFNX) delivered earnings and revenue surprises of 4.00% and -50.25%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Pfenex (PFNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 1 year ago

Pfenex has been struggling lately, but the selling pressure may be coming to an end soon.

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor in Pfenex Inc. (PFNX).

Seeking Alpha - 1 year ago

PFNX develops biosimilars to major drugs approaching patent expiry.

Seeking Alpha - 1 year ago

Pfenex's (PFNX) CEO Eef Schimmelpennink on Q1 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Pfenex (PFNX) delivered earnings and revenue surprises of 52.00% and 84.05%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Pfenex (PFNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor in Pfenex.

Zacks Investment Research - 1 year ago

Pfenex (PFNX) delivered earnings and revenue surprises of 29.03% and -46.64%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 1 year ago

Wall Street analysts see Pfenex reporting a loss of 35 cents per share on revenue of $4.4 million.

About PFNX

Pfenex, a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidate include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis. The company also develops PF743, a recombinant crisantaspase; PF745, a recombinant crisantaspase with half-life extension technology; and PF810, a peptide based next generation therapeutic which is in preclinical development, as well as offers sparX-1 (PF753) and sparX... [Read more...]

Industry
Biotechnology
IPO Date
Jul 24, 2014
CEO
Evert B. Schimmelpennink
Employees
88
Stock Exchange
NYSE American
Ticker Symbol
PFNX
Full Company Profile

Financial Performance

Financial Statements